Schizophrenia Research最新文献

{"title":"Trauma and hallucinations across the sensory modalities: the importance of considering experiences in childhood and adulthood","authors":"Mikaela Bere ,&nbsp;Susan L. Rossell ,&nbsp;Denny Meyer ,&nbsp;Julia D. Nicholls ,&nbsp;Stephen Halperin ,&nbsp;Wei Lin Toh","doi":"10.1016/j.schres.2026.01.009","DOIUrl":"10.1016/j.schres.2026.01.009","url":null,"abstract":"<div><div>It is widely acknowledged that trauma is related to auditory hallucinations in psychotic disorders. Yet, this relationship has not been well explored in hallucinations across other sensory modalities. The current study investigated whether hallucination modality groups (auditory, visual, olfactory, tactile, multisensory) were significantly related to physical, sexual, or emotional trauma. The age at which the trauma was experienced (16 or below, 17 and above) was also considered. Multivariate linear models, analysis of variance, and regression analyses for sixty-six participants with a psychotic disorder sought to determine whether trauma was related to hallucinations. Specifically, we used a modified version of the Life-Stressor Checklist Revised and the Multimodal Hallucinations Schedule (MHS) to identify whether the number of trauma items endorsed, or severity of trauma, at different developmental stages were significantly associated with the severity of lifetime hallucinations across different modalities, and the number of hallucination modalities experienced. We found that the severity of visual hallucinations was significantly associated with a history of sexual trauma. Notably, we revealed that experiencing sexual trauma in both childhood and adulthood was related to an increased self-reported severity of the trauma, and possibly the severity of visual hallucinations. These preliminary findings suggest that type of trauma may be uniquely related to specific hallucination modality and severity. Further, it is important to consider adulthood traumas as well as those occurring in childhood. These results have implications for clinical assessment and intervention.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"289 ","pages":"Pages 71-78"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use and outcomes of antipsychotic medications for delusional and paranoid personality disorders: A population-based study","authors":"Ana Gonzalo-deMiguel ,&nbsp;Sofía Abascal-Peiró ,&nbsp;Prescription Study Group ,&nbsp;Gonzalo Martínez-Alés ,&nbsp;Enrique Baca-García","doi":"10.1016/j.schres.2025.12.010","DOIUrl":"10.1016/j.schres.2025.12.010","url":null,"abstract":"","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 35-37"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145820547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between negative symptoms and health-related quality of life and functional outcomes in persons with schizophrenia: A systematic review","authors":"Allyssa Chan ,&nbsp;Andy Lu ,&nbsp;Trisha Menon ,&nbsp;Sabrina Wong ,&nbsp;Kyle Valentino ,&nbsp;Gia Han Le ,&nbsp;Christine E. Dri ,&nbsp;Roger S. McIntyre","doi":"10.1016/j.schres.2025.12.019","DOIUrl":"10.1016/j.schres.2025.12.019","url":null,"abstract":"<div><h3>Background</h3><div>Negative symptoms in schizophrenia (SCZ) are core phenomenological characteristics known to affect health-related quality of life (HRQoL) and functioning. This systematic review aims to synthesize extant literature to evaluate/elucidate the effect of negative symptoms on HRQoL and functional outcomes in persons with SCZ, as well as to better understand the association between HRQoL and functional outcomes.</div></div><div><h3>Method</h3><div>A systematic search was conducted from inception to July 24, 2025, using Pubmed, MedLine, Embase, AMED, PsychInfo, and Scopus. All studies were independently screened by three reviewers (A.C., A.L., T.M.). Primary studies reporting on the association between negative symptoms, HRQoL, and/or functional outcomes in persons with SCZ were included.</div></div><div><h3>Results</h3><div>We included 68 relevant studies. Most studies were observational and cross-sectional, while others employed case-control, before–after without control, or randomized controlled trial designs. A consistent, small, negative correlation was observed between the presence and severity of negative symptoms and HRQoL (<em>r</em> = −0.67 to 0.69), as well as functional outcomes (<em>r</em> = −0.85 to 0.63. A slight positive association was found between functional outcomes and HRQoL (<em>r</em> = −0.63 to 0.58).</div></div><div><h3>Conclusion</h3><div>Our findings underscore the significant impact of negative symptoms on critical patient-reported outcomes, including HRQoL and functional outcomes. Notwithstanding their clinical importance, there is limited research on negative symptoms, and more research is needed on treatments that address negative symptoms directly, emphasizing the urgent need for targeted therapeutic development.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 95-103"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145926934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychotic-like experiences, suicidal thoughts and behaviours, and non-suicidal self-injury in young offenders","authors":"Andrew Stickley ,&nbsp;Johan Isaksson ,&nbsp;Roman Koposov ,&nbsp;Tomiki Sumiyoshi ,&nbsp;Vladislav Ruchkin","doi":"10.1016/j.schres.2025.12.009","DOIUrl":"10.1016/j.schres.2025.12.009","url":null,"abstract":"<div><h3>Background</h3><div>Research has indicated that both suicidal thoughts and behaviours (STBs) and the prevalence of psychotic-like experiences (PLEs) are elevated in incarcerated young offenders. However, as yet, there has been no research on the PLEs-STBs association in this population. To address this research gap, the current study examined the association between PLEs and STBs (i.e., suicidal ideation and suicide attempts), and non-suicidal self-injury (NSSI) in a sample of male adolescents who were incarcerated in Northern Russia.</div></div><div><h3>Methods</h3><div>Semi-structured psychiatric interviews and self-reports were used to obtain information from 370 young offenders aged 14 to 19 (mean age 16.4 years). The Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) was used to assess PLEs, STBs, NSSI, and co-occurring psychiatric disorders. Binary and ordinal logistic regression were used to assess associations.</div></div><div><h3>Results</h3><div>Almost one-third of the sample (31.6 %) had lifetime PLEs. Lifetime PLEs were significantly associated with STBs in an analysis that also included psychiatric disorders (OR = 1.79). A similar result was obtained for the association between PLEs and NSSI (OR = 2.02), when co-occurring psychiatric disorders were included in the analysis.</div></div><div><h3>Conclusions</h3><div>PLEs were prevalent in this sample of male adolescents serving custodial sentences and associated with higher odds of both STBs and NSSI. Screening for PLEs in the context of broader mental health assessments and interventions during institutional placement may be important for reducing STBs and NSSI in this population.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 59-65"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145865102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of schizotypal disorder: A systematic review and GRADE evaluation of the certainty of evidence","authors":"Kristina Ballestad Gundersen ,&nbsp;Benjamin Arnfred ,&nbsp;Nikolai Albert ,&nbsp;Andreas Rosén Rasmussen ,&nbsp;Bjørn H. Ebdrup ,&nbsp;Andrea Polari ,&nbsp;Barnaby Nelson ,&nbsp;Louise Birkedal Glenthøj","doi":"10.1016/j.schres.2025.12.008","DOIUrl":"10.1016/j.schres.2025.12.008","url":null,"abstract":"<div><h3>Background</h3><div>Evidence to guide treatment for schizotypal disorder is scarce, and clinical guidelines remain undeveloped. This systematic review synthesized current evidence on pharmacological and psychotherapeutic interventions targeting clinical symptoms, cognition, and functioning in schizotypal disorder.</div></div><div><h3>Methods</h3><div>We searched PsychINFO, Embase, Medline, and Cochrane Register of Controlled Trials (25/03/2025) without date restrictions, supplemented by handsearching. Eligible studies were screened, quality appraised, and data extracted by two independent authors. Due to substantial heterogeneity, findings were synthesized narratively, and evidence certainty was rated using GRADE.</div></div><div><h3>Results</h3><div>Twenty-one studies met inclusion criteria. Most had some concerns regarding risk of bias. Pharmacological trials most frequently investigated antipsychotics, with preliminary evidence suggesting benefits of thiothixene and, to a lesser extent, risperidone, olanzapine, and haloperidol in reducing general psychiatric symptoms, although effects on depressive symptoms were mixed. Dopamine agonists and central alpha-2A agonists showed domain-specific cognitive improvements, particularly when combined with cognitive remediation therapy and social skills training. Among psychotherapeutic approaches, metacognitively oriented and evolutionary systems therapies demonstrated consistent symptom reductions, while integrated interventions temporarily reduced negative symptoms and psychosis risk. Functional improvements were most evident in multimodal interventions combining pharmacological and psychosocial components. Across interventions, the overall certainty of evidence was graded very low to low.</div></div><div><h3>Conclusions</h3><div>Current treatment evidence for schizotypal disorder is limited and heterogeneous. Larger, high-quality randomized controlled trials are needed to establish efficacy across clinical, cognitive, and functional domains and to inform development of evidence-based treatment guidelines.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 3-17"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schizotypal traits and daily social functioning: Insights from ecological momentary assessment","authors":"Madisen T. Russell ,&nbsp;Wei Wu ,&nbsp;Michelle P. Salyers ,&nbsp;Tess F. Filip ,&nbsp;Sarah Akhras ,&nbsp;Heather Busanet ,&nbsp;Amanda McCleery ,&nbsp;Katharine N. Thakkar ,&nbsp;Kyle S. Minor","doi":"10.1016/j.schres.2025.12.011","DOIUrl":"10.1016/j.schres.2025.12.011","url":null,"abstract":"<div><div>Elevated schizotypal traits are a risk factor for developing schizophrenia and other forms of psychopathology. Because schizophrenia is marked by social functioning difficulties, examining how schizotypal traits shape everyday interactions can clarify early risk processes. Although ecological momentary assessment (EMA) has been used to examine social interaction likelihood (how often people interact), depth (complexity of content in interactions), and enjoyment (pleasure derived from interactions) in people with schizophrenia, few have explored differences in social interactions across schizotypal traits (positive, negative, and disorganized). This study used EMA to evaluate how positive, negative, and disorganized schizotypal traits in college students (<em>n</em> = 185) relate to social interaction likelihood, depth, and enjoyment in daily life. Given their established role in social functioning and their complex relationships with schizotypal traits, we also investigated whether affect and stress predict individuals' concurrent likelihood, depth, and enjoyment of social interactions. Results revealed that negative traits more strongly predicted reduced social interaction likelihood (<em>B</em> = −0.02, <em>p</em> = .04) and enjoyment (<em>B</em> = -0.06, <em>p</em> &lt; .01) compared to positive (likelihood: <em>B</em> = 0.01, <em>p</em> = .37; enjoyment: <em>B</em> = 0.03, <em>p</em> = .02) and disorganized (likelihood: <em>B</em> = 0.00, <em>p</em> = .85; enjoyment: <em>B</em> = -0.04, <em>p</em> = .04) traits. Contrary to hypotheses, positive affect emerged as the strongest predictor of social interaction outcomes, surpassing negative affect and stress. Additionally, we observed a significant interaction between positive schizotypal traits and negative affect (<em>B</em> = -0.01, <em>p</em> = .03), such that individuals higher in positive traits showed a stronger reduction in enjoyment when experiencing negative affect. These findings enhance our understanding of how schizotypal traits and affect impact daily social interactions and may inform future personalized interventions designed to improve social functioning deficits in at-risk individuals.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 69-76"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145884700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Issue Highlights","authors":"","doi":"10.1016/S0920-9964(26)00018-6","DOIUrl":"10.1016/S0920-9964(26)00018-6","url":null,"abstract":"","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Page A1"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluating the assessment of nonverbal behavior in psychosis symptomatology: A call for cultural sensitivity","authors":"Julianna M. Schuch ,&nbsp;Danielle N. Pratt ,&nbsp;Claudia M. Haase ,&nbsp;Yang Qu ,&nbsp;Vijay A. Mittal","doi":"10.1016/j.schres.2025.12.007","DOIUrl":"10.1016/j.schres.2025.12.007","url":null,"abstract":"","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 1-2"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145766056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual glymphatic roles in first-episode schizophrenia and clinical high-risk for psychosis: Evidence from diffusion tensor image analysis along the perivascular space index","authors":"Siya Peng ,&nbsp;Xiujuan Geng ,&nbsp;Winky Wing Kee Huen ,&nbsp;Catherine Ziqian Fang ,&nbsp;Joe Kwun Nam Chan ,&nbsp;Ryan Sai Ting Chu ,&nbsp;Eric Yu-Hai Chen ,&nbsp;Sherry Kit Wa Chan ,&nbsp;Edwin Ho Ming Lee ,&nbsp;Christy Lai Ming Hui ,&nbsp;Wing Chung Chang","doi":"10.1016/j.schres.2025.12.014","DOIUrl":"10.1016/j.schres.2025.12.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Emerging evidence has implicated glymphatic dysfunction in schizophrenia-spectrum disorders (SSD), yet its role during early stages of the disease remains unclear. To clarify its involvement in pathophysiological mechanisms in the early illness course, we evaluated glymphatic function in first-episode SSD (FES) and clinical high-risk for psychosis (CHR-P) populations using diffusion-tensor image analysis along perivascular space (DTI-ALPS) index, testing whether it would exhibit progressive deterioration or transient compensatory adaptation.</div></div><div><h3>Methods</h3><div>We examined 55 FES patients, 23 individuals with CHR-P and 30 healthy controls (HCs). ANCOVAs were conducted on the global and bilateral DTI-ALPS indices across the three groups, adjusting for age, sex, and head motion. Partial correlation analyses further examined associations between DTI-ALPS index and measures on severity of various symptom dimensions, functioning, and cognitive performance of FES and CHR-P samples.</div></div><div><h3>Results</h3><div>After controlling for covariates, group comparisons revealed that FES patients showed significantly lower global and bilateral DTI-ALPS indices than HCs, while CHR-P did not differ from HCs. Antipsychotic dosage and FES diagnostic subtypes showed no significant differences in DTI-ALPS indices. Correlation analyses showed that, after correction for multiple comparisons, ALPS indices showed no significant correlations with symptoms or cognitive performance. But in the uncorrected analyses, the FES and CHR-P groups showed opposite patterns of correlations with symptoms and cognition.</div></div><div><h3>Conclusions</h3><div>These findings indicate that glymphatic dysfunction is a prominent feature of FES, while early signs of dysfunction may already be present during the prodromal stage. DTI-ALPS index show potential as a stage-specific marker pending longitudinal validation and replication.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 26-34"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145820517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)","authors":"Inder Kaul ,&nbsp;Amy Claxton ,&nbsp;Soumya Chaturvedi ,&nbsp;Tejendra Patel ,&nbsp;Hsiuanlin Wu ,&nbsp;Sharon Sawchak ,&nbsp;Colin Sauder","doi":"10.1016/j.schres.2025.12.015","DOIUrl":"10.1016/j.schres.2025.12.015","url":null,"abstract":"<div><h3>Background</h3><div>The M₁/M₄ muscarinic receptor agonist xanomeline combined with the peripherally restricted pan-muscarinic receptor antagonist trospium chloride is the first approved treatment for adults with schizophrenia with no direct D₂ dopamine receptor blockade. Xanomeline and trospium chloride (KarXT) reduced symptoms and was generally well tolerated in adults with schizophrenia in three, 5-week, randomized, double-blind, placebo-controlled trials and a 52-week, open-label extension trial.</div></div><div><h3>Methods</h3><div>EMERGENT-5 (<span><span>NCT04820309</span><svg><path></path></svg></span>) was a 52-week, open-label trial evaluating the long-term safety, tolerability, and efficacy of twice daily KarXT (maximum dose 125/30 mg) in psychiatrically stable adults with schizophrenia. Safety measures included treatment-emergent adverse events (TEAEs), vital signs, and laboratory parameters. Efficacy measures included change in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI<img>S).</div></div><div><h3>Results</h3><div>Between June 2021–May 2024, 566 participants at 54 US sites received ≥1 dose of KarXT. Overall, 277/566 (48.9 %) participants completed the trial. A total of 466/566 (82.3 %) experienced ≥1 TEAE, the majority of which were mild or moderate in intensity; severe TEAEs were reported in 33/566 (5.8 %) participants. The most common TEAEs occurring in ≥5 % of participants were nausea (23.1 %), vomiting (20.3 %), constipation (18.0 %), hypertension (10.4 %), diarrhea and dry mouth (9.4 % each), dizziness (8.8 %), headache (8.1 %), dyspepsia (7.2 %), somnolence (6.2 %), weight decreased (5.7 %), and hyperhidrosis (5.1 %). KarXT improved PANSS total, PANSS positive and negative subscale, and CGI-S scores over the trial duration.</div></div><div><h3>Conclusions</h3><div>Psychiatrically stable adults with schizophrenia were safely switched from prior antipsychotics to KarXT with a trend toward symptom improvement over 1 year. The safety and tolerability profile of KarXT was consistent with observations in prior clinical trials; no new safety issues emerged.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"288 ","pages":"Pages 86-94"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145926933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}